Loading...
Inhibrx Biosciences, Inc. Common Stock When Issued
INXBV•NASDAQ
NaN
NaN
$13.92
$-2.07(-12.95%)
U.S. Market is Open • 10:05Inhibrx Biosciences, Inc. Common Stock When Issued (INXBV) AI-Powered Stock Analysis
See how Inhibrx Biosciences, Inc. Common Stock When Issued scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerInhibrx Biosciences, Inc. Common Stock When Issued (INXBV) Stock Overall Grade
Inhibrx Biosciences, Inc. Common Stock When Issued’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Inhibrx Biosciences, Inc. Common Stock When Issued's overall stock rating.
Forecast
C+Score
50/100Financial Growth
CScore
40/100Fundamental Growth
C+Score
50/100Key Ratios
C+Score
55/100Sector Comparison
C+Score
50/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
96/100Analyst Consensus
C+Score
50/100Inhibrx Biosciences, Inc. Common Stock When Issued (INXBV) AI-Powered Stock Analysis
This asset demonstrates Normal performance with an overall Forecast Score of 50/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (50/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (50/100, C+) indicate weak positioning. Compared to broader benchmarks like the S&P 500 (96/100, A+), it shows competitive strength. Analyst Consensus (50/100,C+) suggests Low divergence in outlook.Component Analysis Explained
Understand the key factors behind each Inhibrx Biosciences, Inc. Common Stock When Issued stock grade, including financials, comparisons, and forecasts.